{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:59:09Z","timestamp":1791986349758,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SCHA 422\/17-1"],"award-info":[{"award-number":["SCHA 422\/17-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ejca.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T13:17:28Z","timestamp":1628774248000},"page":"268-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients"],"prefix":"10.1016","volume":"155","author":[{"given":"Anne","family":"Zaremba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhardt","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.07.002_bib1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.07.016","article-title":"The concepts of rechallenge and retreatment in melanoma: a proposal for consensus definitions","volume":"138","author":"Gebhardt","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - Update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.12.015","article-title":"Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E\/K-mutant advanced or metastatic melanoma","volume":"109","author":"Robert","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib6","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.002_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2020.03.011","article-title":"Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma","volume":"132","author":"Hemstock","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib8","first-page":"A189","article-title":"308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma","volume":"8","author":"Weber","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2021.07.002_bib9","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.002_bib11","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.002_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib14","article-title":"Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG\/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma","volume":"39","author":"Alexander","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.002_bib17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.07.002_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib19","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.07.002_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2020.03.016","article-title":"Adjuvant immunotherapy: the sting in the tail","volume":"132","author":"Higham","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib21","series-title":"Presented at: AACR annual meeting 2021; April 10-15, 2021; Virtual","article-title":"Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D\/IV melanoma (CheckMate 915)","author":"Long","year":"2021"},{"key":"10.1016\/j.ejca.2021.07.002_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000391","article-title":"Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg\/kg with 3 mg\/kg in patients with advanced melanoma","volume":"8","author":"Ascierto","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib23","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","article-title":"Management of early melanoma recurrence despite adjuvant anti\u2013PD-1 antibody therapy(\u2606)","volume":"31","author":"Owen","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.07.002_bib24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib25","article-title":"Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma","volume":"20","author":"Robert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib26","series-title":"Presented at: the 16th International Society for Melanoma Research Congress November 20-23, 2019","article-title":"Characteristics of long-term survivors and subgroup analyses with combination nivolumab plus ipilimumab for advanced melanoma (CheckMate 067)","author":"Long","year":"2019"},{"key":"10.1016\/j.ejca.2021.07.002_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma","volume":"39","author":"Wolchok","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib28","doi-asserted-by":"crossref","first-page":"S734","DOI":"10.1016\/j.annonc.2020.08.1206","article-title":"1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone","volume":"31","author":"Robert","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.10013","article-title":"Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: phase III KEYNOTE-006 in advanced melanoma","volume":"38","author":"Long","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib31","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamaoncol.2020.2288","article-title":"Association of BRAF V600E\/K mutation status and prior BRAF\/MEK inhibition with pembrolizumab outcomes in advanced melanoma: pooled analysis of 3 clinical trials","volume":"6","author":"Puzanov","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib32","doi-asserted-by":"crossref","first-page":"S762","DOI":"10.1016\/j.annonc.2020.08.1262","article-title":"1139P Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: a pooled analysis of patients with advanced melanoma","volume":"31","author":"Hamid","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2020.11.010","article-title":"Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma","volume":"144","author":"Robert","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib34","first-page":"2100079","article-title":"Pembrolizumab plus ipilimumab following anti\u2013PD-1\/L1 failure in melanoma","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib35","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.19.01464","article-title":"Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade","volume":"38","author":"Betof Warner","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9504","article-title":"Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: updated findings of LEAP-004","volume":"39","author":"Arance","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib37","article-title":"Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047)","volume":"39","author":"Evan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx440.011","volume":"28","author":"Ascierto","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib39","series-title":"Abstract CT072: efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy","author":"Sullivan","year":"2019"},{"key":"10.1016\/j.ejca.2021.07.002_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CMR.0000000000000341","article-title":"Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma","volume":"27","author":"Blasig","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2021.07.002_bib41","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/1346-8138.15408","article-title":"Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma","volume":"47","author":"Kan","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2021.07.002_bib42","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2018.06.005","article-title":"Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression","volume":"101","author":"Bernard-Tessier","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.002_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00262-016-1926-2","article-title":"Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series","volume":"66","author":"Spain","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2021.07.002_bib44","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","article-title":"Discontinuation of anti\u2013PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma","volume":"30","author":"Jansen","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.07.002_bib45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejca.2021.04.021","article-title":"Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti\u2013PD-1 therapy","volume":"153","author":"Hepner","year":"2021","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:52:58Z","timestamp":1778568778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921004275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":45,"alternative-id":["S0959804921004275"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}